targeting innate and adaptive immunity in a phase
play

Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanoma Cara

0 downloads 1 Views 1,36 MB Size Report
  1. Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanoma Cara Haymaker, PhD UT MD Anderson Cancer Center

  2. Presenter Disclosure Information Cara Haymaker The following relationships exist related to this presentation: < ENTER EITHER> <No Relationships to Disclose> <OR> <COMPANY X, Received, Role (i.e. BMS, Honorarium, Speaker)> <COMPANY Y, Received, Role (i.e. Pfizer, Salary, Employee)>

  3. Modulation of the tumor microenvironment by intratumoral administration of the TLR9 agonist IMO-2125 2. 3. Primed T-cells migrate to distant Draining tumor sites Lymph node 1. Intratumoral TLR9 administration of IMO-2125 IFN- α Metastases are targeted by primed T-cells 4. Increased TIL Infiltration CD8 + T cell Dendritic Cell Tumor specific antigens NK cell

  4. Arm 1 Trial Design (NCT02644967) Intratumoral IMO-2125 Ipilimumab i.t. IMO-2125 alone i.t. IMO-2125 + Ipilimumab 1 2 3 4 5 6 7 8 9 10 11 12 13 Week Cycle 1 Cycle 2 Cycle 3 Cycle 4

  5. Key Enrollment Criteria Inclusion Criteria • Diagnosis of metastatic melanoma with stage III (in transit lesions), IVA, IVB, or IVC disease • Progressive disease after treatment with PD-1 inhibitor • ≥ 2 measurable tumor lesions ≥ 1.0 cm • ≥ 18 years • ECOG ≤ 2 • Adequate renal, bone marrow, liver and cardiac function Exclusion Criteria • Received therapy with prior TLR agonist therapy • Symptomatic, unstable or progressing CNS, meningeal, or epidural disease • Concurrent systemic steroid therapy higher than physiologic dose (7.5 mg/day of prednisone) • Active autoimmune disease requiring disease-modifying therapy

  6. Patient Characteristics Data cut off: Oct 07, 2016

  7. Most Frequent Adverse Events AE Preferred Term All, Grade III, Grade IV, N (%) N (%) N (%) Any 10 (100) 5 (50) 1 (10) Nausea 6 (60) 1 (10) - Vomiting 5 (50) - - Anemia 4 (40) 1 (10) - Diarrhea 4 (40) 2 (20) - ALT increase 3 (30) 1 (10) - AST increase 3 (30) - 1 (10) Triglycerides increase 3 (30) - - Chills 3 (30) - - Fatigue 3 (30) - - Pyrexia 3 (30) 1 (10) - Decreased WBC 3 (30) - - Data cut off: Oct 07, 2016

  8. Safety Summary (N=10) IMO-2125 dosing cohort (ipi 3 mg/kg x 4 doses) N subjects with… 4 mg 8 mg 16 mg Total (N=3) (N=4) (N=3) (N=10) ≥ 1 TEAE 3 (100) 4 (100) 3 (100) 10 (100) Related TEAE 2 (67) 4 (100) 2 (67) 8 (80) ≥ 1 SAE 6 (60) ^ 2 (67) 2 (50) 2 (67) Discontinue for AE 0 0 0 0 Death from AE 0 0 0 0 DLT 0 0 0 0 ^ related SAE (IMO or ipi): hypophysitis (2), fever, elevated LFT’s, diarrhea, nausea Data cut off: Oct 07, 2016

  9. Early response data to IMO-2125 + Ipilimumab PR *uCR Treated Patients M PR M Start of Response Ongoing M Mucosal melanoma * Confirmed PR followed by unconfirmed CR 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 Weeks IMO-2125 Dose Assigned 4 mg 8 mg 16 mg Data cut off: Nov. 7, 2016

  10. Tumor Imaging of Patient with a Complete Response: Ipilimumab 3mg plus i.t. IMO-2125 8 mg Pre-Therapy Post-Therapy 03/2016 08/2016 Injected Lesion Distant Lesions

  11. Study 2125-204: Immune response monitoring to correlate with mechanism of action Injected = Injected lesion Distant = Un-injected Lesion Week 8 24 hours post i.t. 5 doses of IMO-2125 and 3 = collection of biopsy Ipilimumab IMO-2125 injection doses of Ipi Pre-dose = collection of PBMCs C1W2 C2W5 C4W11 Injected Distant Injected Injected Distant Tumor Core Formalin - IHC Needle biopsy Fresh flow cytometry DC subsets and maturation Injected Immune infiltrate changes Distant T cell activation/functional state DNA and RNA (TCRseq and gene expression)

  12. Rapid mDC1 maturation induced by IMO-2125 in the tumor Pre-dose 24 hours post i.t. IMO-2125 injection 24 hours post i.t. IMO-2125 injection Pre-dose Injected Injected Dose level 1 (4mg) Dose level 2 (8mg) Dose level 3 (16mg) 1 0 0 % HLA-DR + of mDC1 mDC2 p re d o s e 8 0 CD141 + mDC1 2 4 h r p o s t in je c tio n CD1c + 6 0 * Biopsy delayed to 48hrs 4 0 * 2 0 pDC 0 0 0 0 0 CD303 + 0 P t. 2 P t. 3 P t. 4 P t. 6 P t. 8 P t. 1 0 P t. 1 1 P t. 1 2

  13. Combination therapy induces immune infiltration in distant lesions of responding patients Week 8 Pre-dose IMO-2125 (5) + Ipi (3) Injected Distant Injected Distant Injected Distant 1 0 0 1 0 0 8 0 p re d o s e p re d o s e % C D 4 5 + liv e c e lls % C D 4 5 + liv e c e lls 8 0 C 3 W 8 C 3 W 8 6 0 4 0 6 0 2 0 Lesion 1 0 resolved 4 0 8 6 2 0 4 2 X 0 0.15 0 0 P t. 2 P t. 6 P t. 1 0 P t. 3 P t. 4 P t. 8 P t. 2 P t. 6 P t. 1 0 P t. 3 P t. 4 P t. 8 NR R NR R

  14. Combination therapy induces T cell expansion and activation 24 hours post i.t. Week 8 NE = not evaluable IMO-2125 (5) + Ipi (3) Pre-dose IMO-2125 injection * Biopsy delayed to 48hrs Injected Injected Injected p re d o s e p re d o s e 1 0 0 C 3 W 8 1 0 0 2 4 h r p o s t in je c tio n * C 3 W 8 % C D 5 6 + o f C D 8 + T c e lls 8 0 % K i6 7 + o f C D 8 + T c e lls 8 0 6 0 6 0 4 0 4 0 2 0 2 0 0 0 0 0 0 NE NE 0 0 P t. 2 P t. 6 P t. 1 0 P t. 3 P t. 4 P t. 8 P t. 2 P t. 6 P t. 1 0 P t. 3 P t. 4 P t. 8 NR R NR R

  15. Expansion of top T cell clones in the distant lesion of responding patient Week 8 IMO-2125 (5) + Ipi (3) Pre-dose Injected Distant Injected Distant Non-responding patient Responding patient Frequency of total T cell clones Frequency of total T cell clones predose C3W8 predose C3W8

  16. Late increase in IFN g in patient plasma as a biomarker of response 6 0 NR Additional cytokines assessed Responding TNF a IL-2 IL-10 4 5 IL-6 Pt. 3 Pt. 4 IFN g (p g /m l) Pt. 2 IL-8 IL-12p70 IL-13 3 0 IL-1 b IL-4 1 5 0 C 1 W 1 C 1 W 2 C 2 W 5 C 3 W 8 C 4 W 1 1 C 1 W 1 C 1 W 2 C 2 W 5 C 3 W 8 C 4 W 1 1 C 1 W 1 C 1 W 2 C 2 W 5 C 3 W 8 C 4 W 1 1 P a tie n t tim e p o in t

  17. Where do we go from here? Upregulation of PD-L1 early on therapy p re d o s e 6 0 Predose 24 hr post injection 2 4 h r p o s t in je c tio n % P D -L 1 + ce lls 4 0 2 0 0 20x magnification P t. 2 P t. 3 P t. 4 * Malignant cells only

  18. New Trial Design with addition of IMO-2125 + Pembro Arm (NCT02644967) Intratumoral IMO-2125 i.t. IMO-2125 alone Ipilimumab or Pembrolizumab i.t. IMO-2125 + ipi or pembro * Pembro continues until time of progression 1 2 3 4 5 6 7 8 9 10 11 12 13 Week Cycle 1 Cycle 2 Cycle 3 Cycle 4

  19. Lessons and Take Home Messages • Key points – IMO-2125 results in maturation of intratumoral mDC1 in injected lesion within 24h of drug administration – Increased immune infiltration measured in distant lesions of responding patients at week 8 – Safety is acceptable through 3 dosing cohorts; MTD not yet reached – Preliminary clinical activity with IMO-2125 + ipilimumab in this refractory population is encouraging • Potential impact on the field – Combining intra-tumoral DC activation to enhance T cell priming with checkpoint blockade may be key in IO refractory patient population – A local tumor can be used as a vaccine itself and injection of one lesion results in regression of distant lesions that may not be easily accessible • Lessons learned – On-treatment biopsy timing is critical!!

  20. Acknowledgements MDACC Idera Pharmaceutical Collaborators Adi Diab Chantale Bernatchez Sudhir Agrawal Marc Uemura Daqing Wang Marihella James Sri Chunduru Salah Bentebibel Patients and their families Mark Cornfeld Michael Tetzlaff Jim Geib Patrick Hwu Suzanne Swann Willem Overwijk Kate Lipford MDACC Melanoma Medical MDACC Interventional Oncology Clinicians and Radiology Team Staff Poster #216

Recommend Documents


im immunodeficiency
Im Immunodeficiency (1 (1 of f 2)

Im Immunodeficiency (1 (1 of f 2) Primary ry immunodeficiency diseases

cross kingdom similarity of transcriptional regulation in
Cross-Kingdom Similarity of

Platzhalter fr Bild, Bild auf Titelfolie hinter das Logo einsetzen

using biacore t200 spr system
Using Biacore T200 SPR System

Principles of Immunogenicity Assessment Using Biacore T200 SPR System

update on adult
Update on Adult Describe 3 key

9/28/15 Objectives - Pharmacist Update on Adult Describe 3 key

immunity amp vaccination
Immunity & Vaccination John Helps

Immunity & Vaccination John Helps BVetMed CertSAM MRCVS Senior Technical

drive tumor infiltrating t cell expansion in
drive tumor-infiltrating T-cell

TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T-cell

ud a
UdA CYTOKINES AND CHEMOKINE IN

Professor Pio Conti Director of the Division of Immunology University of

parliamentary immunity
Parliamentary immunity in Poland

Parliamentary immunity in Poland Contents Introduction immunity in the

2 29 16
2/29/16 Adaptive Immune Responses to

2/29/16 Adaptive Immune Responses to Ranaviruses and Immune Evasion

correlates of immunity in vaccinology
Correlates of Immunity in Vaccinology

Correlates of Immunity in Vaccinology Benjamin Kagina bm.kagina@uct.ac.za 11

immunotherapy at ucl uclh
Immunotherapy at UCL/UCLH Karl Peggs

Immunotherapy at UCL/UCLH Karl Peggs Professor of Transplant Science and

corporate presentation
Corporate Presentation June 2019

Corporate Presentation June 2019 NASDAQ/TSX: TRIL This presentation may

nwcsaf convection products v2018 improvements validation
NWCSAF Convection products: v2018

NWCSAF Convection products: v2018 improvements, validation and adaptability

long range facility plan
Long-Range Facility Plan 30 March 2020

Mercer Island School District Long-Range Facility Plan 30 March 2020

cp seminar
CP Seminar 1 Housekeeping Items The

CP Seminar 1 Housekeeping Items The City of Vancouver acknowledges that it

c
C UNTY C MMUNITY C LLEGE

HNSON C UNTY C MMUNITY C LLEGE FACILITIES MASTER PLAN BOARD MEETING

homeostatic
Homeostatic Disruptions and the

Homeostatic Disruptions and the Immune System Disruptions to Dynamic

immunobricks bricks immuno immunobricks immunobricks
Immunobricks bricks Immuno

Immunobricks bricks Immuno Immunobricks Immunobricks toprepare ahi-tech

te tekna na cepi s mission and activit vities ies rega
Te Tekna na CEPIs mission and activit

Te Tekna na CEPIs mission and activit vities ies rega garding ding COVI

to fight cancer
TO FIGHT CANCER Company presentation

ACTIVATING THE PATIENTS IMMUNE SYSTEM TO FIGHT CANCER Company presentation

leveraging the natural strengths of humanity and our
Leveraging the natural strengths of

KIADIS PHARMA | COMPANY PRESENTATION | NOVEMBER 2019 EURONEXT: KDS

selecting for immune
Selecting for Immune Competence in

ImmuneDEX: Measuring and Selecting for Immune Competence in Angus Presented